TESAMORELIN
Long-term efficacy maintained:
Clinical studies demonstrate that tesamorelin treatment resulted in sustained decreases in visceral adipose tissue over 52 weeks without loss of effectiveness.
The reduction in visceral adipose tissue was maintained in patients who continued treatment until week 52 in extension phases of clinical trials
Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy - PubMed.
Does NOT suppress endogenous GH production:
Tesamorelin activates growth hormone-releasing hormone receptors in the pituitary, which leads to synthesis and release of growth hormone
Tesamorelin - LiverTox - NCBI Bookshelf - it stimulates rather than replaces.
Unlike direct human growth hormone injections, tesamorelin maintains the natural feedback loop of the hypothalamic-pituitary axis, with lower risk of growth hormone receptor desensitization
Tesamorelin For Beginners: Benefits, Dosage, and Peptide Stacking Tips – Swolverine.
Effects don't persist after stopping:
Upon discontinuation of tesamorelin, visceral adipose tissue reaccumulated, indicating effects are sustained only during treatment
Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation - PubMed.
IPAMORELIN
Potential for desensitization with continuous use:
Chronic treatment with ipamorelin in young female rats increased body weight gain and enhanced in vitro basal and ipamorelin-stimulated growth hormone release, with results suggesting that ipamorelin does not lead to desensitization of the growth hormone response, while growth hormone-releasing hormone produces desensitization in vitro
(PDF) Chronic in vivo Ipamorelin treatment stimulates body weight gain and growth hormone (GH) release in vitro in young female rats.
ANECDOTAL- non- clinical:
Ipamorelin is well-tolerated long-term due to its selective action and low desensitization risk compared to older peptides
Ipamorelin Cycle Guide: Optimal Dosage, Timing, and Best Peptide Stack – Swolverine, though sustained use requires cycling protocols, with a typical 12-week cycle including 8 weeks of active dosing followed by a 4-week break to prevent receptor desensitization
Ipamorelin Dosage Cycle: How To Plan It – FTW Training.
Does NOT shut down natural GH production:
Ipamorelin does not suppress the body's own feedback loop or downregulate natural growth hormone production, even with long-term use, making it suitable for extended peptide cycles without risking endocrine shutdown
Ipamorelin: What It Is, How It Works, and Why It’s Popular.
Growth hormone secretagogues promote pulsatile release of growth hormone that is subject to negative feedback, which may prevent supratherapeutic levels of growth hormone
The Safety and Efficacy of Growth Hormone Secretagogues - PMC.
KEY DIFFERENCE FROM EXOGENOUS GH
Exogenous GH suppresses natural production:
Previous studies support the concept that exogenous growth hormone can regulate its own secretion through an autofeedback mechanism, with the growth hormone response to growth hormone-releasing factor being significantly inhibited after exogenous growth hormone treatment
Exogenous growth hormone inhibits growth hormone-releasing factor-induced growth hormone secretion in normal men - PMC.
Exogenous growth hormone administration in humans attenuates the endogenous growth hormone response to pharmacological stimuli, with pretreatment completely blocking the serum growth hormone response to growth hormone-releasing hormone
Effect of exogenous growth hormone administration on endogenous growth hormone secretion induced by a met-enkephalin analog - PubMed.
Peptides stimulate, don't replace:
Growth hormone secretagogues including peptides like sermorelin, ipamorelin, and tesamorelin nudge the body to produce its own growth hormone, maintaining natural rhythms and potentially minimizing risks compared to direct growth hormone supplementation
Growth Hormone Peptides: The difference between Sermorelin, Ipamorelin, and Tesamorelin.
